Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
ONCOTHROMB: nieuwe risicoscore voor kankergeassocieerde VTE
mei 2023 | Benigne hematologie, Longoncologie, Maag-darm-leveroncologie